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Host defense peptides are naturally occurring peptides
that have an important function in innate immune
responses in almost every life form. Recently it has been
documented that several host defense peptides have antic-
ancer activity. Based on a naturally occurring host defense
peptide, we have do novo designed the short chemically
modified peptide LTX-315. We have demonstrated that
LTX-315 induces an immunogenic type of cell death with
subsequent release of danger signals (e.g. HMBG1, ATP
and Cytochrome C) and tumor associated antigens
(TAA’s). In addition LTX-315 also has the ability to
directly modulate immune-responses.
In a novel rat mescenhymal sarcoma model (rTMSC) we
demonstrate that LTX-315 induces a complete tumor
regression by intratumoral (i.t.) injection. Studies on trea-
ted tumor tissue confirmed massive necrosis and infiltra-
tion of immune cells. Successfully treated animals were
protected against re-challenge with the tumor cell type
treated, but not against other types of tumor cells. More-
over, tumor resistance could be adoptively transferred by
spleen cells from LTX-315-treated animals. The resistance
was abrogated by depletion of T-lymphocytes.
To clarify whether intratumoral injection of LTX-315 in
one tumor lesion can have an effect on metastatic disease,
intraperitoneal tumor and two subcutaneous tumors were
established in the animals. Thereafter, LTX-315 was
injected into one of the subcutaneous lesion and tumor
growth assessed by living imaging. The results showed
that LTX-315 eradicated all three lesions and the animal
went into durable complete remission.
We propose that by targeting tumor locally LTX-315
can be used for individualized therapeutic in situ vaccina-
tion against cancer.
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